112 results
8-K
MIRM
Mirum Pharmaceuticals Inc
31 May 24
Other Events
5:24pm
is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
8 May 24
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
4:04pm
the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things
NT 10-K
e16kf4zba4jzvd1o
28 Feb 24
Notice of late annual filing
5:01pm
8-K
EX-99.1
is4w ya5e
28 Feb 24
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
u3zif7mps29gn52c
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
424B5
iz6jqi5 q6
2 Nov 23
Prospectus supplement for primary offering
4:59pm
8-K
EX-99.1
0przknc42uptqnpyk
2 Nov 23
Results of Operations and Financial Condition
4:06pm
8-K/A
EX-99.3
kg7zj tc6ih
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-99.4
kokob nzpuc24
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K
0ho1tolrxu4nk9bgr5
17 Oct 23
Other Events
4:39pm
S-3ASR
o9nz61vjd yy6ycr9
13 Oct 23
Automatic shelf registration
4:47pm
8-K
EX-99.1
va00e0va rzrbwwqj8
13 Oct 23
Other Events
4:16pm
8-K
EX-99.1
i528yvpff0jlb9b
5 Sep 23
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
8:36am